Neurocrine Biosciences (NBIX) traded lower on Friday, March 27, 2026, extending weakness tied to investor concerns around the company’s 2026 trajectory for INGREZZA, its largest revenue driver. The stock’s roughly 3% decline fits a “risk-off” reaction in which the market is discounting potential pressure from higher rebates, Medicare-related dynamics, and tighter access that could weigh on realized net pricing and margins just as spending rises for late-stage R&D. (simplywall.st)

Another sentiment overhang is the recent Phase 3 failure for INGREZZA in cerebral palsy, which reduced near-term expectations for label expansion and reinforced the market’s focus on the durability of INGREZZA’s core franchise rather than incremental new-growth levers. When a high-profile trial misses, the next sessions often see incremental de-risking and profit-taking even without a new headline, particularly in large-cap biotech names with a concentrated earnings base. (fiercepharma.com)

With the stock sensitive to commercial assumptions, investors are likely to focus on any updates to INGREZZA demand, gross-to-net trends, and 2026 expense cadence in management commentary and conference appearances. Near term, further clarity on payer behavior and the trade-off between volume growth and net pricing will be key to determining whether the current pullback stabilizes or deepens. (fool.com)